肝内胆管癌经动脉放射性栓塞的剂量-反应与生存分析:多中心多分区剂量学研究
这项多中心回顾性单臂队列研究纳入194例肝内胆管癌患者,分析钇-90玻璃或树脂微球经动脉放射性栓塞后的剂量-反应与生存。180例生存分析显示中位总生存17.4个月(玻璃微球)与16.6个月(树脂微球)无差异(p=0.80);树脂微球亚组中钇-90 PET剂量学的肿瘤吸收剂量与应答呈正相关趋势(AUC 0.693,p=0.028)。
要点
- 玻璃与树脂微球的中位总生存无显著差异(17.4 vs 16.6个月,p=0.80)。
- 树脂微球亚组中钇-90 PET剂量学的肿瘤吸收剂量与应答呈正相关趋势。
- 毒性可接受,仅1例出现2级肝毒性及不可逆肝衰竭。
核心结论
- TARE可能为肝内胆管癌患者提供令人鼓舞的生存结局且毒性可接受,包括挽救治疗场景。
- 在树脂微球亚组中,基于钇-90 PET剂量学评估发现肿瘤吸收剂量与应答之间存在潜在剂量-反应关联。
- 鉴于回顾性多中心设计及成像方式异质性,这些发现应视为假设生成性,需前瞻性研究采用标准化治疗后剂量学确认。
研究设计与样本
- 多中心回顾性单臂队列研究,纳入2014年1月至2024年12月间13个中心接受钇-90玻璃或树脂微球叶或段式TARE的成年肝内胆管癌患者。
- 初始纳入194例(110女,84男;平均年龄53.8±16.6岁);排除无生存状态数据后180例纳入总生存分析;排除17例治疗后钇-90成像不理想者后,163例患者共194次TARE会话纳入剂量-反应分析。
- 治疗后剂量估算由一名有10年剂量计算经验的核医学医师使用Hermia软件VoxelDosimetry工具集中完成,计算平均灌注肝吸收剂量(PLAD)、平均肿瘤吸收剂量(TAD)和平均全肝吸收剂量(WLAD),钇-90 SPECT/CT与PET/CT分别分析。
- 肿瘤应答通过比较治疗前6周内与治疗后2-4个月影像评估,分为客观应答(完全缓解+部分缓解)和无应答(稳定疾病+进展疾病);肝毒性按CTCAE分级,使用TARE后3个月内血清AST、ALT和胆红素水平;计算治疗前后ALBI评分并分析ALBI分级变化。
主要发现
- 给药活度中位数(最小值-最大值):玻璃微球2.7(1.4-6.1)GBq,树脂微球1.4(0.6-1.8)GBq(p=0.004)。
- SPECT与PET研究分别分析中,PET剂量学分析的会话观察到更高的TAD和PLAD值(平均TAD:249.2±26.6 Gy vs 114.8±15.7 Gy,p<0.001;平均PLAD:102.1±10.4 Gy vs 59.4±11.3 Gy,p=0.031)。
- 树脂微球会话中使用钇-90 PET剂量学时,TAD与应答类别之间观察到显著正趋势(曲线下面积0.693,p=0.028)。
- 180例总生存分析(中位随访13.3个月,范围7-81)中发生128例死亡;玻璃与树脂微球的中位OS无差异[17.4(13.2-21.5,95%CI)vs 16.6(7.7-25.5,95%CI)个月,p=0.80]。
- 107例纳入进展时间(TTP)分析的患者中,玻璃与树脂微球的中位TTP无显著差异[12.1(7.8-12.4,95%CI)vs 14.5(5.6-14.4,95%CI)个月,p=0.11]。
关键数值与推荐
- 肿瘤应答分为客观应答(完全缓解+部分缓解)和无应答(稳定疾病+进展疾病),基于治疗前6周内与治疗后2-4个月影像比较。
- 肝毒性按CTCAE分级,使用TARE后3个月内血清AST、ALT和胆红素水平;ALBI评分治疗前后计算并分析分级变化。
- 剂量学参数包括平均灌注肝吸收剂量(PLAD)、平均肿瘤吸收剂量(TAD)和平均全肝吸收剂量(WLAD),由Hermia软件VoxelDosimetry工具集中计算。
临床怎么用
- TARE可作为肝内胆管癌的治疗选择,包括挽救治疗场景,玻璃与树脂微球生存结局无显著差异。
- 树脂微球治疗时,基于钇-90 PET的剂量学评估可能有助于预测肿瘤应答,但需前瞻性标准化验证。
- 治疗后应监测肝毒性,包括AST、ALT、胆红素及ALBI分级变化。
局限性
- 回顾性多中心设计。
- 成像方式异质性。
- 发现应视为假设生成性,需前瞻性研究采用标准化治疗后剂量学确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We aimed to report real-world outcomes of transarterial radioembolization (TARE) in patients with intrahepatic cholangiocarcinoma (ICC), focusing on different microsphere types and posttreatment dosimetric approaches in relation to dose-response and survival analyses. MATERIALS AND METHODS: This multicenter retrospective single-arm cohort study included adult patients with intrahepatic cholangiocarcinoma treated with Y-90 glass or resin microspheres using lobar or segmental approaches between January 2014 and December 2024 across 13 centers. All posttreatment Y-90 Bremsstrahlung single photon emission tomography (SPECT)/ computed tomography (CT) or Y-90 positron emission tomography (PET) images were reviewed. Post-treatment dose estimations were performed centrally by a nuclear medicine physician with 10 years of experience in dosimetric calculations using the VoxelDosimetry tool of Hermia software (Hermes Medical Solutions, Sweden). Mean perfused liver absorbed dose (PLAD), mean tumor absorbed dose (TAD), and mean whole-liver absorbed dose (WLAD) were calculated. Dosimetric analysis for Y-90 SPECT/CT and PET/CT were performed separately. Tumor response was assessed by comparing imaging obtained within 6 weeks before treatment and 2-4 months after treatment. Response categories were grouped as objective response (complete response + partial response) and nonresponse (stable disease + progressive disease) for treated lesions. Hepatotoxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) using serum Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and bilirubin levels within 3 months after TARE. Additionally, albumin-bilirubin (ALBI) scores were calculated before and after treatment, and changes in ALBI grade were analyzed. RESULTS: Initially, data from 194 (110 female, 84 male; mean age 53.8 ± 16.6 years) patients were included. After excluding patients without survival status data, 180 patients were included in the overall survival (OS) analysis. Seventeen patients were excluded from dose-response evaluation due to suboptimal posttreatment Y-90 imaging for dosimetric calculations. Survival analyses were performed on a per-patient basis, whereas dosimetric and response analyses were performed on a per-treatment-session basis. For dose response analysis, a total of 194 TARE sessions in 163 (101 female, 62 male; mean age 51.4 ± 12.6 years) patients were analyzed. Median (min-max) of administered activities were 2.7 (1.4-6.1) GBq for glass microspheres and 1.4 (0.6-1.8) GBq for resin microspheres (p = 0.004). In separate analyses of SPECT and PET studies, higher TAD and PLAD values were observed in sessions analyzed with PET-based dosimetry (for mean TAD; 249.2 ± 26.6 Gy vs 114.8 ± 15.7 Gy, p < 0.001, for mean PLAD; 102.1 ± 10.4 Gy vs 59.4 ± 11.3 Gy, p = 0.031). A significant positive trend between TAD and response category was observed in the resin microsphere sessions using Y-90 PET-based dosimetry (Area Under Curve 0.693, p = 0.028). In the OS analysis of 180 patients (median follow-up 13.3 months, range 7-81), 128 deaths occurred. Medians of OS did not differ between patients treated with glass versus resin microspheres [17.4 (13.2-21.5, 95%CI) vs 16.6 (7.7-25.5, 95%CI) months, p = 0.80]. Among 107 patients included in time to progression (TTP) analysis, no significant difference in medians of TTP was observed between patients treated with glass and resin microspheres [12.1 (7.8-12.4, 95%CI) vs 14.5 (5.6- 14.4, 95%CI) months, p = 0.11]. One patient developed grade 2 hepatotoxicity and irreversible hepatic failure 10 months after a second TARE session due to tumor progression. In addition, cholangitis occurred in 1 patient and gastritis in 3 patients following TARE. CONCLUSION: This multicenter analysis suggests that TARE may provide encouraging survival outcomes with acceptable toxicity in patients with ICC, including salvage settings. A potential dose-response association was identified in the resin microsphere subgroup evaluated with Y-90 PET-based dosimetry. Given the retrospective multicenter design and heterogeneity of imaging modalities, these findings should be considered hypothesis-generating and require confirmation in prospective studies using standardized posttreatment dosimetry.
引用
- Soydal C, Ones T, Bozkurt MF, et al. Dose-Response and survival analysis after transarterial radioembolization for intrahepatic cholangiocarcinoma: A multicenter multicompartment dosimetry study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42332191. doi:10.1007/s00259-026-08007-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。